Enhanced expression of interleukin 8 (CXCL8) in cystic fibrosis (CF) airway epithelial (AE) cells Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interleukin (IL) 1-beta in small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Relationship between interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), C-reaktive protein (CRP), albumin (ALB) and alkaline phosphatase (ALP) in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 98s Year: 2006
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Interleukin -18 (IL-18) and tumor necrosis factor (TNF) in sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002
Experimental infection with respiratory viruses enhances interleukin (IL) 5-excretion in culture supernatants of primary cultured human peribronchial gland cells (PBGC) Source: Eur Respir J 2001; 18: Suppl. 33, 272s Year: 2001
Impared endotoxin-induced Interleukin (IL) -5 and Interferon- (IFN) γ expression in peripheral blood T-lymphocytes from atopic asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 291s Year: 2003
Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011
Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Interleukin 27 (IL27): A new tool for lung cancer gene immunotherapy? Source: Annual Congress 2012 - Special problems in thoracic surgery Year: 2012
The Role of Signal Transducer and Activator of Transcription protein 1 (STAT1) in a murine model of lung adenocarcinoma (ADC) Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Does tumour necrosis factor-alpha (TNF-alpha) induced by lipopolysaccharide have a positive feedback effect on the up-regulation of interleukin-8 (IL-8) messenger RNA by monocytes from COPD patients? Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013
Alveolar lymphocytes (AL) produce interleukin 27 (IL27), antigen presenting cell-secreted cytokine. Increased expression of IL27 in bronchoalveolar lavage (BAL) of pulmonary sarcoidosis (PS) patients Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
The haplotypes of interleukin 10 but not that of tumour necrosis factor alpha/lymphotoxin alpha and interleukin 1 cluster are associated with susceptibility for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 105s Year: 2005